• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    IM Cannabis to Report First Quarter 2024 Financial Results on Wednesday, May 8th at 9:00am ET

    5/1/24 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $IMCC alert in real time by email

    TORONTO and GLIL YAM, Israel, May 1, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2024 ended March 31, 2024, on Wednesday, May 8, 2024, before the market opens.

    IM Cannabis Corp.

    The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.

    If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.

    Link for the zoom call: https://us02web.zoom.us/webinar/register/WN_4MfaN9x7SLm1B9Zr0Asw8w

    About IM Cannabis Corp.

    IMC (NASDAQ:IMCC) (CSE:IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

    The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution center, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries. The Company has exited operations in Canada and considers these operations discontinued.

    Company Contact:

    Anna Taranko, Director Investor & Public Relations

    IM Cannabis Corp.

    +49 157 80554338

    [email protected]

    Oren Shuster, CEO

    IM Cannabis Corp.

    +972-77-3603504

    [email protected]

    Logo - https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/im-cannabis-to-report-first-quarter-2024-financial-results-on-wednesday-may-8th-at-900am-et-302132873.html

    SOURCE IM Cannabis Corp.

    Get the next $IMCC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMCC

    DatePrice TargetRatingAnalyst
    10/5/2021$8.00Buy
    ROTH Capital
    7/14/2021Buy
    Desjardins
    7/14/2021$10.50Buy
    Desjardins
    More analyst ratings

    $IMCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH Capital initiated coverage on IM Cannabis with a new price target

      ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00

      10/5/21 7:57:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Desjardins initiated coverage on IMC Mortgage Co

      Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy

      7/14/21 8:40:32 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Desjardins initiated coverage on IM Cannabis with a new price target

      Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50

      7/14/21 7:01:53 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

      TORONTO and GLIL YAM, Israel, May 7, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (CSE:IMCC) (the "Company" or "IM Cannabis"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, further its news release dated April 11, 2025 (the "April 11 Release"), it has filed a management information circular (the "Circular") in connection with the upcoming annual general and special meeting of the shareholders of the Company ("Shareholders") to be held on May 23, 2025 (the "Meeting"). Capitalized terms not otherwise defined herein have the meanings attributed to them in the April 11 Release.     Meeting Details The Company's board of directors

      5/7/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

      TORONTO and GLIL YAM, Israel, May 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens.     The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the

      5/6/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Provides Corporate Updates

      TORONTO and GLIL YAM, Israel, April 11, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced the following corporate updates.     Nasdaq Notification Letter The Company has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") dated April 9, 2025, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) (the "Listing Rule") requires companies listed on the Nasdaq Capital Market to maintain a minimum of US$2.5 million in stockholders'

      4/11/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Leadership Updates

    Live Leadership Updates

    See more
    • IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

      TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

      9/11/24 8:30:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer

      TORONTO and GLIL YAM, Israel, Oct. 10, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Uri Birenberg will join the company's leadership team as Chief Financial Officer effective October 10, 2023.  This appointment strengthens IMC's financial leadership and strategic direction for achieving sustainable profitability. "We're delighted to welcome Uri as our new Chief Financial Officer at IMC. His impressive track record and extensive experience with large scale international organizations, as well as with startups, make him an outstandin

      10/10/23 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Corp. Appoints Rinat Efrima as New Chief Executive Officer of IMC Holdings, the Company's Israeli Subsidiary

      Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial changes include the promotion of Yael Harrosh to Chief Legal and Operations Officer of IM Cannabis Corp.TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / January 13, 2022 / IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC)(NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany today announced the appointment of Rinat Efrima as the new Chief Executive Officer of IMC Holdings Ltd. ("IMC Holdings"), the Company's wholly-owned Israeli subsidiary. Ms. Efrima will join the Company in the first quarter of 2022. In addition, Ya

      1/13/22 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    SEC Filings

    See more
    • SEC Form 6-K filed by IM Cannabis Corp.

      6-K - IM Cannabis Corp. (0001792030) (Filer)

      5/7/25 7:17:55 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by IM Cannabis Corp.

      6-K - IM Cannabis Corp. (0001792030) (Filer)

      5/6/25 7:28:10 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by IM Cannabis Corp.

      6-K - IM Cannabis Corp. (0001792030) (Filer)

      5/5/25 7:19:52 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by IM Cannabis Corp.

      SC 13G - IM Cannabis Corp. (0001792030) (Subject)

      2/21/23 10:56:41 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by IM Cannabis Corp. (Amendment)

      SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)

      2/8/23 1:29:15 PM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by IM Cannabis Corp. (Amendment)

      SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)

      2/2/23 10:38:01 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Financials

    Live finance-specific insights

    See more
    • IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

      TORONTO and GLIL YAM, Israel, May 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens.     The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the

      5/6/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Reports Fourth Quarter and Full Year 2024 Financial Results

      Q4 2024 Caps a Year of Strategic and Operational Improvements for IMC with 25% Revenue Growth, 42% decrease in Operating Expenses, and $0.5M Adjusted EBITDA Profit TORONTO and GLIL YAM, Israel, March 31, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, is pleased to announce its financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all amounts are reported in Canadian dollars and are compared to the quarter ended December 31, 2023. The Company's audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying manage

      3/31/25 8:39:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ET

      TORONTO and GLIL YAM, Israel, March 20, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the fourth quarter and full year 2024 ended December 31, 2024, on Monday, March 31, 2025 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a

      3/20/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care